Amgen's Bemarituzumab Shows Promise in aGC: Amgen announces positive FORTITUDE-101 trial results, showing bemarituzumab+chemotherapy improves OS in FGFR2b-positive aGC.

Press Release: Amgen’s Bemarituzumab Shows Promise in Advanced Gastric Cancer
@amgen.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Amgen #Bemarituzumab #GastricCancer #GIOnc

FORTITUDE-101 Study Updates 2025: Bemarituzumab Plus mFOLFOX6 in FGFR2b-Positive Gastric and GEJ Cancer - OncoDaily FORTITUDE-101 Study shows that Bemarituzumab Plus mFOLFOX6 improves OS in patients with FGFR2b-Positive Gastric and GEJ Cancer.

FORTITUDE-101 Study Updates 2025: Bemarituzumab Plus mFOLFOX6 in FGFR2b-Positive Gastric and GEJ Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FORTITUDE101 #Bemarituzumab #mFOLFOX6 #GEJCancer #GastricCancer

Amgen Reports Groundbreaking Phase 3 Trial Results for Bemarituzumab in Gastric Cancer Treatment Amgen's Phase 3 trial results for bemarituzumab show significant survival benefits in gastric cancer patients, marking a potential breakthrough in targeted therapy.

Amgen Reports Groundbreaking Phase 3 Trial Results for Bemarituzumab in Gastric Cancer Treatment #United_States #Amgen #Thousand_Oaks #gastric_cancer #Bemarituzumab